FindTrial
Sign In

Assessment of Magnitude of Loss of Muscle mass and strength among Adult Patients with long standing liver disease and Its Impact on death rate at 12 months among theses patients at a Tertiary Health Care Centre of North India.

Assessment of Magnitude of Sarcopenia among Adult Patients with Liver Cirrhosis and Its Impact on Predicted Twelve-Month Mortality at a Tertiary Health Care Centre of North India - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/08/093279
Enrollment
402
Registered
2025-08-19
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K746- Other and unspecified cirrhosis ofliver

Interventions

Intervention1: Nil: Nil

Sponsors

GSVM MEDICAL COLLEGE KANPUR
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age more than or equal to 18 years Ready to participate in the study as per protocol (Consenting) Confirmed diagnosis of liver cirrhosis based on Clinical criteria as Ascites with SAAG ratio equal to or greater than 1.1 presence of esophageal varices past history of hepatic encephalopathy supported by treatment documents Biochemical test Serum Albumin equal to or less than 3.5 mg percent INR greater than 1.3 Imaging Nodular liver architecture seen on ultrasound splenomegaly collateral circulation portal vein size greater 13 mm Alcohol abstinence equal to or greater than 3 months Hemoglobin level equal to or greater than 8 g per dl Stable subjects with co-morbidities like diabetes with HbA1c less than 10 percent hypertension with BP less than SBP 140 and DBP less than 90 mm Hg hypothyroidism or hyperthyroidism with normal thyroid function on appropriate therapy CKD stage 1& 2 will be eligible for participation. They should be on stable dose for last at least three months.

Exclusion criteria

Exclusion criteria: Acute hepatic decompensation Jaundice History of hospitalization in last three months Malignancy CKD (stage equal to or greater than 3) Heart Failure (NYHA III and IV) COPD GOLD Stage III & IV Neuromuscular disease (such as myasthenia gravis) Stroke or other neurologic disorder with residual deficit Infections like HIV active pulmonary or extrapulmonary TB Critical illness Organ transplant or immunosuppression Pregnancy and lactation Long-term steroid use (except inhaled or topical) Bedridden subjects due to their inability in performing the required tests Subjects having locomotor abnormalities

Design outcomes

Primary

MeasureTime frame
Burden of sarcopenia among patients with liver cirrhosis Timepoint: Baseline—

Secondary

MeasureTime frame
impact of Sarcopenia among patients with Liver cirrhosis on predicted twelve-month mortality at a tertiary care center of North India Assessment of quality of life using SARQOLTimepoint: Single—

Countries

India

Contacts

Public ContactSharad Kotriwala

GSVM Medical College

kotriwala.sharad@gmail.com9241780470

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026